Vaccines

US demand to reach $7.4 billion in 2008

US demand for vaccines will advance 8.6 percent per annum to $7.4 billion in 2008. Several factors will underlie growth, including an increasing emphasis on prevention in human and veterinary medicine, the commercialization of new and improved products, the upgrading of defense systems against bioterrorism, the expansion of infant and child health care programs, aging demographic trends, the strengthening of food safety regulations, rising pet ownership, and a greater availability of pet health insurance.

Pediatric preparations to remain dominant human vaccine

Pediatric preparations will remain the top-selling group of vaccines due to well-established safety and effectiveness criteria, improving product formulations and a large number of potential new patients. About 40 percent of US children are not fully immunized in line with recommended schedules advocated by the Centers for Disease Control and Prevention and other medical organizations. Attempts to extend coverage to a larger percentage of children will benefit growth opportunities for pediatric vaccines, especially RSV, pneumococcal, DTaP, measles-mumps-rubella and varicella preparations.

Based on a large potential patient base, hepatitis preparations will continue to generate the second-largest sales volume among vaccines. However, unfavorable demographic trends will temper hepatitis A vaccine. A decreasing number of unvaccinated adults, attributable largely to the previous immunization of health care workers, will soften growth in demand for hepatitis B vaccines.

Biodefense vaccines, consisting of preparations against anthrax and smallpox, will sustain moderate gains in demand over the next several years as the ongoing threat of bioterrorism prompts the government to build and maintain supplies. With annual shots recommended for most of the population and new formulations extending product availability, influenza vaccines will generate strong long-term growth opportunities. The anticipated introduction of new vaccines for SARS will underlie the above average sales gains projected for travel vaccines.

AIDS, cancer vaccines to bolster long-term prospects

New product introductions against an expanding range of disease targets will represent the key force leading to rapid growth opportunities for other human vaccines. Within the next half decade, advances in biotechnology and related life science disciplines are expected to bring the first vaccines for AIDS, cancer, herpes and West Nile virus into the US marketplace. By 2013, several additional vaccines will be approved for the prevention of these diseases, contributing vast improvements to national health and living standards.

Veterinary vaccines showing market maturity

Growth in veterinary vaccines demand will lag the pace of human vaccines due to greater market maturity; more limited opportunities to develop new, large-selling products; and ongoing safety controversies. More favorably, advances in biotechnology and related life science fields will lead to the introduction of improved preparations for a number of high value-added niche applications. The market for veterinary vaccines will continue to be divided between products that promote food safety and products indicated for maintaining the health and wellness of companion animals.

Study coverage

This new Freedonia study, Vaccines, presents historic US demand data through 2003 plus forecasts to 2008 and 2013 for human and veterinary vaccines by type. The study also examines the US market environment, reviews principal vaccine technologies, details industry structure, presents company market share data and profiles 25 leading industry competitors.